drugset / Trial / NCT00239408

Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).

NCT00239408

Phase 4 Completed 311 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary disease (COPD), is affected by smoking status.

Timeline

Start
2002-12
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 18 ug Inhaled